Home -> Law Blog Directory -> Patent Law Blogs -> Patentablydefined.com
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patentablydefined.comRecent Decisions of the Board of Patent Appeals and Interferences Confirm the Need for an Adequate Rational to Modify/Combine
By mike
© 2008, Michael E. Kondoudis
A colleague passed along the results of a brief survey of some recent Board of Patent Appeals and Interferences (BPAI) decisions in which the BPAI cited KSR and reversed claim rejections. Two aspects of the survey results stood out. Of the 43 reversals identified by the search, 24 were based on a failure of the cited art to meet every feature of a rejected claim while 11 were based on an Examiner?s failure to provide sufficient reasoning for an asserted combination/modification.
This admittedly incomplete survey appears to indicate two things about current appeal practice. First, some Examiners still fail to address each and every claim feature, so continue to argue that asserted combination(s) is/are deficient, when appropriate. Second, challenges to the sufficiency of a proffered rationale to combine/modify appear to still have some bite, despite KSR?s ?affirmation? that the proper inquiry for motivation is not limited to the overly rigid teaching suggestion motivation (TSM) test and Leapfrog?s confirmation that ?the common sense of those skilled in the art demonstrates why some combinations would have been obvious where others would not.?
One last point, recent BPAI decisions provide useful guidance on how to effectively argue non-obviousness in light of KSR, and they are available at www.uspto.gov/go/dcom/bpai.
www.mekiplaw.com
Full post as published by Patentablydefined.com on March 31, 2008 (boomark / email).
Unwed Fathers' Rights in Adoption
Landmark Cases in Adoption Law Shape Law with respect to Unwed Fathers
Health Insurers
Dictating Medical Decisions
Personal Injury
Appeals Court Upholds Congressional Legislation
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Microsoft Corp.
allegedly failed to provide adequate access and service to Xbox Live and its subscribers.

A New Day, New Rules: Ex Parte Appeals Before the Board of Patent Appeals and Interferences
Board of Patent Apeals and Interferences (BPAI)
Board of Patent Appeals and Interferences (BPAI)
Attorneys: New USPTO Patent Appeals Rules Will Raise Costs, Accomplish Little
USPTO News: Patent Office to Publish New Appeals Rules on Tuesday
BPAI: when prior art teaches away, expectation of success cannot support obviousness rejection








